RxDoctor Payments Data

Ijeoma Nwuju, DPM

Podiatrist · Bethesda, MDNPI 1902224959

Payments from drug & device makers

What this record shows

This record is dominated by other: $584,947 of the $600,991 with a category attached, or 97.3%. Convatec Inc. accounts for 97.4% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $420,716, more than ten times the $3,725 reported in 2019. Among podiatrist clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$600,991in general payments, 2019–2025

Across 96 payments — averaging $6260.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Convatec Inc.$585K
  • Supreme Orthopedic Systems, LLC$13K
  • Triad Life Sciences Inc.$2K
  • Lifenet Health$1K
  • Organogenesis Inc.$168
  • Amgen$125
  • plus $198 from 5 others

What the payments were for

  • Travel & lodging$2,0840%
  • Food & beverage$1,5270%
  • Education$12,4332%
  • Other$584,94797%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$600,991 in reported general payments places this provider in the 95th percentile of 183 podiatrist providers in Maryland.

See all podiatrist providers in Maryland

Medicare billing

Part B allowed, 2024
$114,110
Medicare patients
152
Services billed
721

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole113$155,236
SantylCollagenase Clostridium Hist.14$4,930
Ammonium Lactate145$2,699
Clotrimazole119$1,807
Diclofenac Sodium18$794
Gentamicin Sulfate14$625
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip12$381
CiclopiroxCiclopirox Olamine16$344
ErythromycinErythromycin Base In Ethanol15$309
Mupirocin18$204
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen13$137
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim14$65
Naproxen11$38

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$52$4,93014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 183 podiatrist providers in Maryland.

Other podiatrist in Bethesda

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →